
SplitNov 18, 2026, 04:24 PM
Senti Biosciences, Inc. Completes 1-for-33 Reverse Stock Split
AI Summary
Senti Biosciences, Inc. has filed an amendment to its Certificate of Incorporation to effect a 1-for-33 reverse stock split of its common stock. This action was approved by stockholders at the 2026 Annual Meeting and subsequently authorized by the Board of Directors. The reverse stock split is effective November 18, 2026, with trading expected to commence on a split-adjusted basis on November 19, 2026. Fractional shares will be rounded up to the nearest whole share.
Key Highlights
- Senti Biosciences, Inc. effected a 1-for-33 reverse stock split of its common stock.
- The reverse stock split was approved by stockholders at the 2026 Annual Meeting.
- The Board of Directors approved the reverse stock split ratio of 1-for-33.
- Trading on a split-adjusted basis is expected to begin on November 19, 2026.
- Fractional shares resulting from the split will be rounded up to the nearest whole share.
Price Impact
More from SNTI